Changes in Platelet Level and Activation as Hematological Biomarkers of Antipsychotic-Induced Systemic Inflammatory Response: Narrative Review
https://doi.org/10.52667/2712-9179-2026-6-2-10-28
Abstract
Research over the last decade has shown that schizophrenia spectrum disorders (SSDs) cannot be viewed exclusively as a neurotransmitter pathology. A significant proportion of patients, especially those in the acute phase and with treatment resistance, exhibit signs of low-grade inflammation (LGI), which is associated with cardiovascular comorbidity, including the risk of venous thromboembolism (VTE). The role of antipsychotics (APs), which are the mainstay of SSDs therapy, in the development of VTE remains controversial. On one hand, preclinical in vitro and in vivo studies demonstrate an antiplatelet effect of APs. This effect is mediated through blockade of adenosine diphosphate (P2Y1 and P2Y2) and serotonin (5-HT2A) receptors, and inhibition of thromboxane A2. On the other hand, clinical in vivo studies indicate the persistence or even increase of procoagulant platelet activity and LGI, which significantly elevates the risk of VTE in patients with SSDs during long-term AP treatment. Materials and Methods: In this narrative review, we analyzed and summarized the results of preclinical and clinical studies on biomarkers of AP-induced platelet activation, as well as their prognostic role in assessing VTE risk in patients with SSDs. Results: As a result, the knowledge of psychiatrists regarding the potential negative impact on platelet hemostasis has been updated for firstand new-generation APs. It has been shown that asenapine and amisulpride carry the highest risk of developing AP-induced VTE. Haloperidol and droperidol have a dose-dependent risk of VTE. An increased risk of AP-induced pathological bleeding is observed with the use of quetiapine, thioridazine, thiothixene, and flupentixol. Conclusion: The diverse effects of APs on platelet hemostasis have been demonstrated. This underscores the need for a differentiated approach to selecting APs and the complexity of predicting the additive effect during AP polytherapy. Dynamic monitoring of hematological biomarkers (platelet and inflammatory) is important for reducing the risk of developing VTE in patients with SSDs.
Keywords
platelets,
schizophrenia spectrum disorders,
antipsychotic,
hematological biomarker,
platelet hemostasis,
low-grade inflammation,
venous thromboembolism,
pulmonary embolism,
pathological bleeding,
hematological adverse reaction.
Supporting agencies: The study was performed within the framework of the state assignment of the ”Bekhterev’s National Medical Research Center for Psychiatry and Neurology of the Ministry of Health of Russia” (XSOZ 2024 0012).
About the Authors
Regina F. Nasyrova
Institute of Personalized Psychiatry and Neurology, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
3 Bekhterev St., St Petersburg 192019
Natalia A. Shnayder
Institute of Personalized Psychiatry and Neurology, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
3 Bekhterev St., St Petersburg 192019
Anastasiia A. Abramenko
Institute of Personalized Psychiatry and Neurology, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
3 Bekhterev St., St Petersburg 192019
Zarema T. Taygibova
Institute of Personalized Psychiatry and Neurology, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
3 Bekhterev St., St Petersburg 192019
Elmar O. Guseynov
Institute of Personalized Psychiatry and Neurology, V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
3 Bekhterev St., St Petersburg 192019
References
1. Ji G.J., Zalesky A., Wang, Y., et al. Linking personalized brain atrophy to schizophrenia network and treatment response. Schizophrenia Bulletin. 2023; 49(1):43–52. https://doi.org/10.1093/schbul/sbac162
2. Yu Q., Weng W., Zhou H., et al. Elevated platelet parameter in first-episode schizophrenia patients: a cross-sectional study. Journal of Interferon & Cytokine Research. 2020; 40(11): 524–529. https://doi.org/10.1089/jir.2020.0117
3. Manoubi S.A., Boussaid M., Brahim O., et al. Fatal pulmonary embolism in patients on antipsychotics: case series, systematic review and meta-analysis. Asian Journal of Psychiatry. 2022; 73,103105. https://doi.org/10.1016/j.ajp.2022.103105
4. Chari D., Sawhney I., Mukaetova-Ladinska E., et al. Risk factors for deep vein thrombosis and pulmonary embolism: a comparative study between acute hospital care and mental health inpatient settings for older people. Working with Older People. 2025; 29(3):254–265. https://doi.org/10.1108/WWOP-06-2024-0031
5. Osimo E.F., Perry B.I., Cardinal R.N., et al. Inflammatory and cardiometabolic markers at presentation with first episode psychosis and long-term clinical outcomes: a longitudinal study using electronic health records. Brain, Behavior, and Immunity. 2021; 91:117-127. https://doi.org/10.1016/j.bbi.2020.09.011
6. Li H., Li W., Zhang X., et al. Association of antipsychotic drugs with venous thromboembolism in patients with schizo-phrenia: a systematic review and meta-analysis. General Psychiatry. 2023; 36(5):e101347. https://doi.org/10.1136/gpsych-2023-101347
7. Khoodoruth M.A.S., Tarteel H., Sami O., et al. Peripheral inflammatory and metabolic markers as potential biomarkers in treatment-resistant schizophrenia: insights from a Qatari cohort. Psychiatry Research. 2025; 344:116307. https://doi.org/10.1016/j.psychres.2024.116307
8. Ekwere T.A., Effiong J.H. Assessing the risk of venous thromboembolism in psychiatric patients on antipsychotic medication using platelet indices. International Journal of Medical and Health Sciences. 2017;6(3):134-138. https://doi.org/10.9790/6737-0603134138
9. Zhdanov R.I., Doinikova A.N., Zhdanova S.I., et al. Correlation between haemostatic and vegetate nervous system param-eters under examination stress. Zhurnal Vyssheinervnoi Deiatelnosti imeni I. P. Pavlova. 2016; 66(2):202–208. (In Russian)
10. Brusov O.S., Karpova N.S., Oleichik I.V., et al. The decrease in procoagulant activity of blood during combined therapy with antidepressants and antipsychotics in patients with endogenous mental disorders. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova. 2021; 121(4):30-36. https://doi.org/10.17116/jnevro202112104130 (in Russian)
11. Morozova M.A., Burminsky D.S., Beniashvili A.G., et al. Association of the effectiveness of therapy for an acute psychotic episode in patients with schizophrenia with the activity of platelet enzymes. Psikhiatriya. 2023; 21(3):6-15. https://doi.org/10.30629/2618-6667-2023-21-3-6-15 (in Russian)
12. Zheng Y., Zhou X., Chen K., et al. Neutrophil/lymphocyte ratio is increased in the acute phase of schizophrenia and re-gardless the use and types of antipsychotic drugs. BMC Psychiatry. 2024; 24(1): 876. https://doi.org/10.1186/s12888-024-06330-w
13. Kosidou S., Zannas Z., Ofrydopoulou A., et al. Psychotropic and neurodegenerative drugs modulate platelet activity via the PAF pathway. Neurochemistry International. 2025; 191:106073. https://doi.org/10.1016/j.neuint.2025.106073
14. Wu, C.C., Tsai, F.M., Chen, M.L., et al. Antipsychotic drugs inhibit platelet aggregation via p2y1 and p2y12 receptors. Biomed Res Int. 2016; 2016: 2532371. https://doi.org/10.1155/2016/2532371
15. Zheng C., Liu H., Tu W., et al. Hypercoagulable state in patients with schizophrenia: different effects of acute and chronic antipsychotic medications. Therapeutic Advances in Psychopharmacology. 2023; 13: 20451253231200257. https://doi.org/10.1177/20451253231200257
16. State Register of Medicines. Available at: https://grls.pharm-portal.ru/grls
17. U.S. Food and Drug Administration (FDA). Available at: https://www.fda.gov
18. Wallaschofski H., Eigenthaler M., Kiefer M., et al. Hyperprolactinemia in patients on antipsychotic drugs causes adp-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. Journal of Clinical Psychopharmacology. 2003; 23(5):479-483. https://doi.org/10.1097/01.jcp.0000088914.24613.51
19. National Center for Biotechnology Information (NCBI). Glycoprotein IIb/IIIa Inhibitors. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK554376/
20. Ogłodek, E.A., Just, M.J., Grzesińska, A.D., et al. The impact of antipsychotics as a risk factor for thromboembolism. Phar-macological Reports. 2018; 70(3): 533-539. https://doi.org/10.1016/j.pharep.2017.12.003
21. Patrono C., Rocca B. Measurement of thromboxane biosynthesis in health and disease. Front. Pharmacol. 2019; 10:1244. https://doi.org/10.3389/fphar.2019.01244
22. Takada Y.K., Wu C.Y., Takada Y. PF4 autoantibody complexes cause activation of integrins αiibβ3 and αvβ3 and possible subsequent thrombosis and autoimmune diseases. Int. J. Mol. Sci. 2025; 26(21):10260. https://doi.org/10.3390/ijms262110260
23. Patti G., Nenna A., Spadoni F., et al. β-thromboglobulin as a biomarker of platelet activation and predictor of cardiovascular events: a systematic review and meta-analysis. Stroke. 2025; 56(3): 712-723. https://doi.org/10.1161/STROKEAHA.124.049972
24. Marengo M., Migliori M., Merlotti G., et al. Role of the cd40-cd40 ligand pathway in cardiovascular events, neurological alterations, and other clinical complications of chronic hemodialysis patients: protective role of adsorptive membranes. Blood Purification. 2023; 52(1): 27-42. https://doi.org/10.1159/000530808
25. Tourjman V., Kouassi É., Koué M.È., et al. Antipsychotics' effects on blood levels of cytokines in schizophrenia: a me-ta-analysis. Schizophrenia Research. 2013; 151(1-3): 43–47. https://doi.org/10.1016/j.schres.2013.10.011
26. Zhang Y., Ehrlich S.M., Zhu Q., Du S. Signaling mechanisms of the platelet glycoprotein Ib-IX complex. Platelets. 2022; 33(6): 823-832. https://doi.org/10.1080/09537104.2022.2071852
27. Hajjiah A., Maadarani O., Bitar Z., et al. Antipsychotic drugs may contribute to venous thromboembolism – a case report and review of literature. JRSM Open. 2023; 14(1): 20542704221132142. https://doi.org/10.1177/20542704221132142
28. National Center for Biotechnology Information (NCBI). Platelet-Activating Factor. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK557392/
29. Ollivier V., Syvannarath V., Gros A., et al. Collagen can selectively trigger a platelet secretory phenotype via glycoprotein VI. PloS One. 2014; 9(8): e104712. https://doi.org/10.1371/journal.pone.0104712
30. Hering J., Amann B., Angelkort B., Rottmann M. Thrombin-antithrombin III-complex and prothrombin fragment F1+2 in arterial and venous blood of patients with peripheral arterial disease. Vasa. 2003; 32(4): 193-197. https://doi.org/10.1024/0301-1526.32.4.193
31. Hemant G., Indranil B., Alireza R.R. Thrombomodulin: a multifunctional receptor modulating the endothelial quiescence. Journal of Thrombosis and Haemostasis. 2024; 22(4): 905-914. https://doi.org/10.1016/j.jtha.2024.01.006
32. Zaidi S.R.H., Rout P. Interpretation of blood clotting studies and values (PT, PTT, aPTT, INR, anti-factor Xa, D-dimer) [Up-dated 2025]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK604215/
33. Ishioka M., Yasui-Furukori N., Sugawara N., et al. Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers. Neuropsychiatr. Dis. Treat. 2015; 11:477-484. https://doi.org/10.2147/NDT.S75176
34. Santoro R.C., Molinari A.C., Leotta M., Martini T. Isolated prolongation of activated partial thromboplastin time: not just bleeding risk. Medicina (Kaunas, Lithuania). 2023; 59(6):1169. https://doi.org/10.3390/medicina59061169
35. Chornenki N.L.J., Fralick M., Sholzberg M. International normalized ratio and activated partial thromboplastin time testing. CMAJ:Canadian Medical Association journal. 2022; 194(33):E1135. https://doi.org/10.1503/cmaj.220629
36. Hsu E., Moosavi L. Biochemistry, Antithrombin III. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK545295/
37. Dorgalaleh A., Favaloro E.J., Bahraini M., Rad F. Standardization of Prothrombin Time/International Normalized Ratio (PT/INR). International Journal of Laboratory Hematology. 2021; 43(1):21–28. https://doi.org/10.1111/ijlh.13349
38. Croquet V., Vuillemin E., Ternisien C., et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur. J. Gastro-enterol. Hepatol. 2002; 14(10): 1133-1141. https://doi.org/10.1097/00042737-200210000-00015
39. Carrizo E., Fernández V., Quintero J., et al. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophrenia Research. 2008; 103(1-3): 83–93. https://doi.org/10.1016/j.schres.2008.03.004
40. Pinjari O.F., Dasgupta S.K., Okusaga O.O. Plasma soluble P-selectin, Interleukin-6 and S100B protein in patients with schizophrenia: a pilot study. Psychiatr. Q. 2022; 93(1): 335-345. https://doi.org/10.1007/s11126-021-09954-3
41. Ma Y.Q., Xu Z., Zhu J. Integrin αIIbβ3. In: Gresele, P., López, J.A., Angiolillo, D.J., Page, C.P. (eds) Platelet Physiology I. Platelets in Thrombotic and Non-Thrombotic Disorders. Springer, Cham. 2025. doi: 10.1007/978-3-031-96340-7_12
42. Debaene C.B., Feys H.B.A.B., Six K.R.A. Shedding light on GPIbα shedding. Current Opinion in Hematology. 2024; 31(5):224-229. https://doi.org/10.1097/MOH.0000000000000826
43. Chawla D., Saad E., Khairi T., Padmanabhan A. Severe persistent heparin-induced thrombocytopenia in a renal transplant patient. Thrombosis Research. 2019; 183:106–107. https://doi.org/10.1016/j.thromres.2019.10.014
44. Oruch R., Hodneland E., Pryme I.F., Holmsen H. Psychotropic drugs interfere with the tight coupling of polyphospho-inositide cycle metabolites in human platelets: a result of receptor-independent drug intercalation in the plasma membrane?. Biochimica et Biophysica Acta. 2008; 1778(10): 2165–2176. https://doi.org/10.1016/j.bbamem.2008.04.007
45. Bertha B.G., Sill J.C., Berger I., et al. High-dose droperidol protects against experimental coronary thrombosis in dogs and pigs and attenuates aggregation of porcine platelets and Ca2+ mobilization in human platelets. Anesthesiology. 1993; 78(4):733–743. https://doi.org/10.1097/00000542-199304000-00017
46. Instructions for medical use of the drug - Haloperidol. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%A1-000645/InstrImg_2021_05_26_1469341/ae771f5a-f866-47eb-84b0-40eec18a8908.pdf
47. Instructions for medical use of the drug - Droperidol. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_001100_-_%D0%A0%D0%93-RU_/InstrImg_2022_09_09_1486781/1fa961c9-e598-45c1-bf20-3e4593c1c915.pdf
48. Instructions for medical use of the drug - Zuclopenthixol. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_011913_-_%D0%A0%D0%93-RU_/InstrImg_2026_02_02_1525913/f35eb14c-aac7-480e-a721-3372c5a54974.pdf
49. Instructions for medical use of the drug - Tizercin. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_000079_-_%D0%A0%D0%93-RU_/InstrImg_2021_5_27_1469415/%D0%9B%D0%9F-%E2%84%96(000079)-(%D0%A0%D0%93-RU)[2020]_0.pdf
50. Singh A.N., Barlas C., Saeedi H., Mishra R.K. Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia. Journal of Psychiatry & Neuroscience. 2003; 28(1), 39–47.
51. Instructions for medical use of the drug - Periciazine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_006400_-_%D0%A0%D0%93-RU_/InstrImg_2024_12_03_1511622/4d5ae6f6-4c61-4a1e-ac54-9b11b5f75fa7.pdf
52. Suzuki O., Seno H., Kumazawa T. In vitro inhibition of human platelet monoamine oxidase by phenothiazine derivatives. Life Sciences. 1988; 42(21): 2131–2136. https://doi.org/10.1016/0024-3205(88)90127-0
53. Instructions for medical use of the drug - Perphenazine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_012481_-_%D0%A0%D0%93-RU_/InstrImg_2025_12_22_1524535/f9bd41a0-8a03-4601-9c1c-55e39a0fd4b0.pdf
54. Mcfarland R.B. Fatal drug reaction associated with prochlorperazine (compazine). report of a case characterized by jaundice, thrombocytopenia, and agranulocytosis. American Journal of Clinical Pathology. 1963; 40:284–290. https://doi.org/10.1093/ajcp/40.3.284
55. Instructions for medical use of the drug - Sulpiride. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_008846_-_%D0%A0%D0%93-RU_/InstrImg_2025_03_25_1515313/f930f6cd-1fec-4bbd-90ff-58f13153ac3f.pdf
56. Instructions for medical use of the drug - Thioproperazine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9F_N014904_01/InstrImg_2021_03_30_5409/ca8cddcb-52b5-4fa9-b5bf-7980b83c8eab.pdf
57. Instructions for medical use of the drug - Thioridazine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_010434_-_%D0%A0%D0%93-RU_/InstrImg_2025_06_25_1518539/8e02b14b-28e4-4671-bc6b-77f36d2b7268.pdf
58. Balon R., Berchou R., Zethelius M. Thrombocytopenia associated with chlorpromazine, haloperidol and thiothixene: a case report. Canadian Journal of Psychiatry. 1987; 32(2):149–150. https://doi.org/10.1177/070674378703200213
59. Holmsen H., Daniel J.L., Dangelmaier C.A., et al. Differential effects of trifluoperazine on arachidonate liberation, secretion and myosin phosphorylation in intact platelets. Thrombosis Research. 1984; 36(5), 419–428. https://doi.org/10.1016/0049-3848(84)90298-6
60. Instructions for medical use of the drug - Trifluoperazine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9F_N015130_01/InstrImg_2023_06_19_1496225/ec94b864-40ea-4d0a-9936-5c6d71c60144.pdf
61. Instructions for medical use of the drug - Flupentixol. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-005281/InstrImg_2021_12_20_1476543/d8f8ef36-89a0-41b5-9b0a-50efa003a0df.pdf
62. Holt R.J. Neuroleptic drug-induced changes in platelet levels. Journal of ClinicalPpsychopharmacology. 1984; 4(3):130–132.
63. Zubenko G.S., Cohen B.M. In vitro effects of psychotropic agents on the microviscosity of platelet membranes. Psychophar-macology. 1984; 84(2):289–292. https://doi.org/10.1007/BF00427463
64. Pandey S.C., Sharma R.P., Janicak P.G., Marks R.C., Davis J.M., Pandey G.N. Platelet serotonin-2 receptors in schizophrenia: effects of illness and neuroleptic treatment. Psychiatry Research. 1993; 48(1):57–68. doi: 10.1016/0165-1781(93)90113-u
65. Instructions for medical use of the drug - Fluphenazine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_004077_-_%D0%A0%D0%93-RU_/InstrImg_2024_01_24_1501346/fbc57572-788e-457b-b8c7-bdc20110bb79.pdf
66. Holmsen H., Rygh, T. Chlorpromazine makes the platelet plasma membrane permeable for low-molecular weight substances and reduces ATP production. Biochemical Pharmacology. 1990; 40(2), 373–376. doi: 10.1016/0006-2952(90)90701-l
67. Warlow C., Ogston D., Douglas A.S. Platelet function after the administration of chlorpromazine to human subjects. Hae-mostasis. 1976; 5(1):21–26. https://doi.org/10.1159/000214115
68. Instructions for medical use of the drug - chlorpromazine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_001706_-_%D0%A0%D0%93-RU_/InstrImg_2024_02_06_1501740/8e2be4ba-9a8e-41a2-9133-a7ebcb6e208d.pdf
69. Instructions for medical use of the drug - chlorprothixene. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_000203_-_%D0%A0%D0%93-RU_/InstrImg_2021_4_28_1468593/%D0%9B%D0%9F-%E2%84%96(000203)-(%D0%A0%D0%93-RU)[2021]_0.pdf
70. Instructions for medical use of the drug - asenapine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-001526/InstrImg_2020_06_13_27412/f1b2224a-ca14-4da0-b4c2-b3cfbd23bdc2.pdf
71. Şengül M.C., Kaya K., Yilmaz A., et al. Pulmonary thromboembolism due to paliperidone: report of 2 cases. The American Journal of Emergency Medicine. 2014; 32(7):814.e1–814.e8142. https://doi.org/10.1016/j.ajem.2013.12.038
72. Instructions for medical use of the drug - amisulpride. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_012917_-_%D0%A0%D0%93-RU_/InstrImg_2025_12_30_1524945/42f0a04c-1f68-4390-ac3f-473ea03fe940.pdf
73. Instructions for medical use of the drug - ziprasidone. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_003752_-_%D0%A0%D0%93-RU_/InstrImg_2025_09_12_1521409/97c8fb2e-61ce-404a-bdcc-6ed21d19b357.pdf
74. Instructions for medical use of the drug - Quetiapine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_004607_-_%D0%A0%D0%93-RU_/InstrImg_2024_03_11_1502662/e70afdef-a62b-4995-9347-c8d8bd3bba08.pdf
75. Gligorijević N., Vasović T., Lević S., et al. Atypical antipsychotic clozapine binds fibrinogen and affects fibrin formation. International Journal of Biological Macromolecules. 2020; 154:142-149. https://doi.org/10.1016/j.ijbiomac.2020.03.119
76. Instructions for medical use of the drug - clozapine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_011446_-_%D0%A0%D0%93-RU_/InstrImg_2025_09_16_1521486/b0d83477-5a93-4dc1-b590-027829ea9a62.pdf
77. Rafi M., Goyal C., Reddy P., Reddy S. Lurasidone induced thrombocytopenia: is it a signal of drug induced myelosuppres-sion? Indian Journal of Psychological Medicine. 2018; 40(2): 191–192. https://doi.org/10.4103/IJPSYM.IJPSYM_374_17
78. Instructions for medical use of the drug - Lurasidone. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_011432_-_%D0%A0%D0%93-RU_/InstrImg_2025_09_04_1520983/728d4b45-574d-4ed3-99e3-6c687fbbc3b2.pdf
79. Bokhari S.A., Butaher H., Saleem R., Elhassan N. Olanzapine-induced thrombocytopenia in a patient with chronic schizo-phrenia: a case report. Cureus. 2024; 16(11):e74677. https://doi.org/10.7759/cureus.74677
80. Rasras H., Beghi M., Samti M., et al. Rare and underestimated association of pulmonary embolism and olanzapine therapy; report of two cases. Archives of Academic Emergency Medicine. 2021; 9(1):e17. https://doi.org/10.22037/aaem.v9i1.1063
81. Maazouzi M., Bouallala A., Haddadi Z., et al. Antipsychotic drugs as a contributing factor of pulmonary embolism: a report of 4 cases. Radiology Case Reports. 2023; 18(5):1997-2000. https://doi.org/10.1016/j.radcr.2023.02.046
82. Instructions for medical use of the drug - Olanzapine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_002284_-_%D0%A0%D0%93-RU_/InstrImg_2023_05_15_1493505/35008e88-73eb-46b5-ac42-93f59f0ecc5d.pdf
83. Lin Y.C., Chen C.W., Chen B.L., Kao Y.T., Huang C.Y. A Case report of chronic thromboembolic pulmonary hypertension after long-term use of risperidone and paliperidone. Acta Cardiologica Sinica. 2020; 36(5):514–516. https://doi.org/10.6515/ACS.202009_36(5).20200526A
84. Yılmaz E.D., Motor S., Sefil, F., et al. Effects of paliperidone palmitate on coagulation: an experimental study. TheScientific-WorldJournal. 2014; 964380. https://doi.org/10.1155/2014/964380
85. Zhang X.R., Zhang Z.J., Jenkins T.A., et al. The effect of chronic antipsychotic drug administration on nitric oxide synthase activity and gene expression in rat penile tissues. European Neuropsychopharmacology. 2010; 20(4):211-217, https://doi.org/10.1016/j.euroneuro.2009.10.002.
86. Instructions for medical use of the drug - Paliperidone. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_003795_-_%D0%A0%D0%93-RU_/InstrImg_2025_05_19_1517377/c29bba5d-e730-4ae9-b3c8-2569c8a4299d.pdf
87. Saxena S.K., Dwivedi A.K., Timothy A., et al. Risperidone-induced thrombocytopenia in a case of psychosis and neuroen-docrine tumor: a case report. Indian Journal of Psychiatry. 2021; 63(3):311–312. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_488_20
88. Instructions for medical use of the drug - Risperidone. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_007087_-_%D0%A0%D0%93-RU_/InstrImg_2024_10_18_1509888/a5b2e6b5-3566-42d6-83d1-c829ad85f179.pdf
89. Instructions for medical use of the drug - Sertindole. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%A1-000615/InstrImg_2024_04_17_1503727/2fcd58d6-5f65-474d-b196-e6a9d51aceeb.pdf
90. Instructions for medical use of the drug - Aripiprazole. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_001283_-_%D0%A0%D0%93-RU_/InstrImg_2022_11_17_1488952/77228122-3caa-4a97-ac83-016331734041.pdf
91. Instructions for medical use of the drug - Brexipiprazole. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-006867/InstrImg_2022_12_05_1489336/525fdef5-8b68-4991-adb6-7816c5604c1a.pdf
92. Instructions for medical use of the drug - Cariprazine. Available at: https://cdn.pharm-portal.ru/69jxs7cjr4n4gdc2acy5y4x8/instructions/%D0%9B%D0%9F-_N_001510_-_%D0%A0%D0%93-RU_/InstrImg_2025_04_14_1516155/f8733f55-8c23-4502-8e68-f40b402395b7.pdf
93. Chen T.Y., Lin C.E., Chen L.F., Tzeng N.S. Enhanced bleeding risk in an elderly dementia patient treated with warfarin and quetiapine. The Journal of neuropsychiatry and clinical neurosciences. 2013; 25(4): E25. https://doi.org/10.1176/appi.neuropsych.12090232
94. Saracoglu H., Karakukcu C., Kilic C., Simsek Y. Potential indicators of bone marrow suppression in patients with schizo-phrenia receiving clozapine: platelet-large cell ratio and immature granulocytes. Psychiatry and Behavioral Sciences. 2024; 14(4): 123-130. https://doi.org/10.5455/PBS.20240301055535
95. Yan P., Gao B., Wang S., et al. Association of 5-HTR2A T102C and A-1438G polymorphisms with clinical response to atypical antipsychotic treatment in schizophrenia: a meta-analysis. Neuroscience Letters. 2022; 770:136395. https://doi.org/10.1016/j.neulet.2021.136395
96. ClinicalTrials.gov. Pharmacogenetics and Therapeutic Drug Monitoring In Schizophrenia (PROMISE). Identifier: NCT05839613. Available at: https://clinicaltrials.gov/study/NCT05839613?tab=study
97. Ivashchenko D.V., Yudelevich D.A., Buromskaya N.I., et al. CYP2D6 phenotype and ABCB1 haplotypes are associated with antipsychotic safety in adolescents experiencing acute psychotic episodes. Drug Metabolism and Personalized Therapy. 2021; 37(1), 47–53. https://doi.org/10.1515/dmpt-2021-0124
98. Singh R., Bansal Y., Medhi B., Kuhad A. Antipsychotics-induced metabolic alterations: Recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. European Journal of Pharmacology. 2019; 844: 231–240. https://doi.org/10.1016/j.ejphar.2018.12.003
99. Josefsson E., Vainchenker W., Chloe J. Regulation of platelet production and life span: role of bcl-xl and potential implications for human platelet diseases. International Journal of Molecular Sciences. 2020; 21: 1-12. https://doi.org/10.3390/ijms21207591
100. Badawy A.Z., Kandel S.H., Ahmedy I.A., et al. Evaluation of Bak and Bcl-Xl gene expression among pediatric patients with acute primary immune thrombocytopenia. Clinical and Experimental Pediatrics. 2025; 68(11):901–908. doi: 10.3345/cep.2025.00997
101. Lindquist I., Olson S.R., Li A., et al. The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis. Platelets. 2022; 33(1): 66–72. doi: 10.1080/09537104.2020.1859102
102. Wu X., Liu Y., Zou C., et al. Nicotine's impact on platelet function: insights into hemostasis mechanisms. Frontiers in Phar-macology. 2025; 15: 1512142. https://doi.org/10.3389/fphar.2024.1512142
103. Hsu W.Y., Lane H.Y., Lin C.L., Kao C.H. A population-based cohort study on deep vein thrombosis and pulmonary embo-lism among schizophrenia patients. Schizophrenia Research. 2015; 162(1–3): 248-252. https://doi.org/10.1016/j.schres.2015.01.012
104. Kaiser R., Anjum A., Nicolai L. Platelet heterogeneity in disease: the many and the diverse? Blood. 2025; 146(24):2870–2881. https://doi.org/10.1182/blood.2025028957
105. SCORE (Systematic Coronary Risk Evaluation) scale. Available at: https://zdrav-nnov.ru/grazhdanam/kalkulyator-zdorovya/shkala-score/
106. Wells Scale for Pulmonary Embolism Probability [Internet]. MSD Manual Professional Edition. Available at: https://www.msdmanuals.com/ru/professional/multimedia/clinical-calculator/
107. Buryachkovskaya L.I., Lomakin N.V., Sumarokov A.B., Shirokov E.A. Efficacy and safety of antithrombotic therapy [venous thrombosis and pulmonary embolism]: scales and algorithms. Therapy Journal. 2018. Available at: https://therapy-journal.ru/articles/Effektivnost-i-bezopasnost-antitromboticheskoi-terapii-venoznyi-tromboz-i-tromboemboliya-legochnoi-arterii-shkaly-i-algoritmy.html
108. Wilkinson K.S., Sparks A.D., Gergi M., et al. Validation of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) risk scores for venous thromboembolism and bleeding in an independent population. Re-search and Practice in Thrombosis and Haemostasis. 2024; 8(4):102441. https://doi.org/10.1016/j.rpth.2024.102441
109. Clinical guidelines "Deep vein thrombosis" (Russian Federation, 2025). Available at: https://diseases.medelement.com/disease/
110. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: November 27, 2017. Available at: https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v5-5x7.pdf
111. Bassand J.P. GUSTO (Global Utilization of Streptokinase and Tissue plasminogen activator in Occluded arteries): logic wins at last. European Heart Journal. 1994; 15(1):2–4. doi: 10.1093/oxfordjournals.eurheartj.a060374
112. Sobieraj D.M., White C.M., Kluger J., et al. Table 1, Thrombolysis in myocardial infarction (TIMI) Flow Grading System. In: Adjunctive Devices for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011. (Comparative Effectiveness Reviews, No. 42). Available at: https://www.ncbi.nlm.nih.gov/books/NBK84280/table/introduction.t1/
113. Lip G.Y., Frison L., Halperin J.L., Lane D.A. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. Journal of the American College of Cardiology. 2011; 57(2): 173–180. https://doi.org/10.1016/j.jacc.2010.09.024
114. Zhu W., Fu L., Ding Y., et al. Meta-analysis of ATRIA versus CHA2DS2-VASc for predicting stroke and thromboembolism in patients with atrial fibrillation. International Journal of Cardiology. 2017; 227: 436–442. https://doi.org/10.1016/j.ijcard.2016.11.015
115. Silverio A., Di Maio M., Buccheri S., et al. Validation of the academic research consortium high bleeding risk criteria in pa-tients undergoing percutaneous coronary intervention: A systematic review and meta-analysis of 10 studies and 67,862 pa-tients. International Journal of Cardiology. 2022; 347: 8–15. doi: 10.1016/j.ijcard.2021.11.015
116. IMPROVE Bleeding Risk Assessment Score [Internet]. Practical-Haemostasis.com. Available at: https://practical-haemostasis.com/Clinical%20Prediction%20Scores/Formulae%20code%20and%20formulae/Formulae/Bleeding-Risk-Assessment-Score/Improve_bleeding_risk_assessment_score.html
117. Zornberg G. L., Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet (London, England). 2000; 356(9237): 1219–1223. https://doi.org/10.1016/S0140-6736(00)02784-7
118. Semiz M., Yücel H., Kavakçı O., et al. Atypical antipsychotic use is an independent predictor for the increased mean platelet volume in patients with schizophrenia: a preliminary study. Journal of Research in Medical Sciences. 2013; 18(7): 561–566.
119. Carrizo E., Fernández V., Quintero J., et al. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophrenia Research. 2008; 1031(3): 83-93. https://doi.org/10.1016/j.schres.2008.03.004
120. Koller D., Almenara S., Mejía G., et al. Metabolic effects of aripiprazole and olanzapine multiple-dose treatment in a ran-domised crossover clinical trial in healthy volunteers: association with pharmacogenetics. Advances in Therapy. 2021; 38(2): 1035–1054. https://doi.org/10.1007/s12325-020-01566-w
121. Obukohwo O.M., Ben-Azu B., Nwangwa E.K., et al. Adverse hematological profiles associated with chlorpromazine anti-psychotic treatment in male rats: preventive and reversal mechanisms of taurine and coenzyme-Q10. Toxicology Reports. 2024; 12:448-462. https://doi.org/10.1016/j.toxrep.2024.04.004
Review
For citations:
Nasyrova R.F., Shnayder N.A., Abramenko A.A., Taygibova Z.T., Guseynov E.O. Changes in Platelet Level and Activation as Hematological Biomarkers of Antipsychotic-Induced Systemic Inflammatory Response: Narrative Review. Personalized Psychiatry and Neurology. 2026;6(2):10-28. https://doi.org/10.52667/2712-9179-2026-6-2-10-28
Views:
73
JATS XML
Email this article 